BURLINGTON, Mass., April 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that most influences their decisions regarding prescribing in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Amgen/UCB's AMG-785/CDP-7851 and Merck's odanacatib have advantages over patient share leader alendronate (Merck's Fosamax, Teijin's Bonalon, generics) on this attribute.
The DecisionBase 2013 report entitled Emerging Therapies AMG-785/CDP-781 and Odanacatib Are Poised to Overtake Teriparatide's Status as the Clinical Gold Standard also finds that, based on clinical data and the opinions of interviewed thought leaders, teriparatide (Eli Lilly's Forteo/Forsteo, Asahi Kasei's Teribone) is Decision Resources' current proprietary clinical gold-standard therapy for osteoporosis and osteopenia. Teriparatide has the strongest clinical profile among key marketed products that treat osteoporosis and osteopenia. However, AMG-785/CDP-7851 is expected to displace teriparatide and will earn proprietary clinical gold-standard status for osteoporosis and osteopenia in 2021, following its launch for the indication in 2017. AMG-785/CDP-7851 has competitive advantages in safety and tolerability as well as delivery over teriparatide and advantages in efficacy and safety over the current standard of care, alendronate.
"It is important to note, however, that AMG-785/CDP-7851 is considered only marginally better than odanacatib, which falls just short of being the future clinical gold standard," said Decision Resources Analyst Pam Narang , Ph.D. "Furthermore, although thought leaders expect AMG-785/CDP-7851 to offer superiority over alendronate across all efficacy attributes, the drug's anticipated safety and tolerability profile gives it the edge over current and emerging osteoporosis and osteopenia agents."
According to insights from surveyed U.S. and European PCPs and managed care organization (MCO) pharmacy directors, greater reduction in the risk of vertebral fracture is one of the greatest unmet needs in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Radius Health's BA-058 and AMG-785/CDP-7851 have demonstrated the potential to significantly fulfill this unmet need.
The report also finds that surveyed U.S. MCO pharmacy directors are particularly receptive to new osteoporosis and osteopenia therapies that offer 50 percent better reduction in the risk of vertebral fractures over currently available therapies. Decision Resources expects that BA-058 and AMG-785/CDP-7851 will match the improvements on vertebral fracture risk reduction that surveyed U.S. payers indicated would be required for widespread inclusion on MCO formularies.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved